London, UK (PRWEB) December 24, 2012
Tumor markers form one of the most important segments of the world cancer diagnostics industry. Recently, the tumor marker market growth has picked up given the enhancing number of cancer affected people and rising cancer mortality. In 2010, the market was evaluated at approximately USD 1 billion. It is likely to grow at a CARG of above 5.5% in 2012-2017. Abbott, Hoffmann-La Roche, Beckman Coulter, Fujirebio Inc. and bioMérieux SA are amid the recognized market players.
Prostate Specific Antigen (PSA), used to screen the men’s prostate cancer, recently has proved to be the only extensively adopted tumor marker. The further market development will be spurred by the technological advancements in tumor diagnostics and treatment and introduction of new antigens.
New market research report “Tumor Markers: Innovative Technologies and Emerging Business Opportunities” worked out by Venture Planning Group (VPG) has been recently published by Market Publishers Ltd.
Title: Tumor Markers: Innovative Technologies and Emerging Business Opportunities
Published: December, 2012
Price: US$ 28,500.00
The report covers the tumor markers market in France, Germany, Italy, Japan, Spain, the UK and the USA. The study thoroughly analyzes the existing and emerging tumor makers, examines technologies and their applications and examines market segments. The information on the market size, shape, dynamics and structure along with outlined business opportunities are available in the research. The report also discloses the assessment of the competitive landscape, identifies the leading companies and profiles the potential market entrants. In addition, the future forecasts for the market are discussed in the research study.
Reasons to Buy:
More new market research reports by the publisher can be found at VPG page.